Erenumab
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Erenumab: From Migraine Prevention to Migraine with Brainstem Aura
One-Sentence Summary
Erenumab is a CGRP-receptor monoclonal antibody already used for general migraine prevention. The TxGNN model predicts it may also be effective for the specific subtype Migraine with Brainstem Aura, with 0 clinical trials and 20 publications (mostly indirect subgroup/secondary analyses) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in this evidence pack (no EU/Taiwan license record); erenumab’s established clinical use per literature is general migraine prevention |
| Predicted New Indication | Migraine with Brainstem Aura |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L2 |
| EU Market Status | ✗ Not marketed (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, formal mechanism-of-action documentation for erenumab is not available in this evidence pack. Based on the repurposing rationale provided, erenumab is a monoclonal antibody that directly blocks the CGRP (calcitonin gene-related peptide) receptor, inhibiting CGRP-mediated activation of the trigeminovascular system — the core pathophysiological pathway underlying migraine.
This predicted indication is not a typical “repurposing” case. Erenumab is already established for migraine prevention broadly; “migraine with brainstem aura” is a specific clinical subtype rather than an unrelated disease. Existing evidence largely comes from secondary/post-hoc analyses of migraine trials that pooled “with and without aura” populations, rather than dedicated randomized trials in the brainstem-aura subtype specifically.
Mechanistically, the rationale is sound: CGRP-mediated trigeminovascular activation is common to migraine with and without aura, including aura subtypes. However, because no trial has isolated the brainstem-aura population, and cardiovascular/vascular safety in aura patients has required dedicated post-hoc scrutiny (e.g., PMID 34928306, 36942409), this is scored L2 rather than L1, reflecting supportive-but-not-subtype-specific evidence.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34928306 | 2022 | RCT (secondary analysis) | JAMA Neurology | Secondary analysis of RCTs assessing erenumab safety/efficacy in migraine with vs. without aura; addresses elevated vascular risk in the aura subgroup |
| 30360965 | 2018 | RCT (Phase 3b) | Lancet | Randomized, double-blind, placebo-controlled trial of erenumab in episodic migraine patients who failed 2–4 prior preventives |
| 37012858 | 2023 | Systematic Review | Int Immunopharmacol | Systematic review of erenumab efficacy in episodic and chronic migraine prophylaxis |
| 36942409 | 2023 | Cohort (post-hoc) | Headache | Pooled long-term trial data assessing cardiovascular safety of erenumab by aura status and CV risk |
| 40275185 | 2025 | Cohort/Biomarker | J Headache Pain | Plasma suPAR (inflammation biomarker) linked to erenumab treatment response |
| 35151970 | 2022 | Cohort (real-world) | Clin Neurol Neurosurg | Croatian real-world effectiveness/safety data in treatment-resistant chronic migraine |
| 32867533 | 2021 | Cohort (physiological) | Cephalalgia | Erenumab does not alter cerebral hemodynamics or endothelial function in migraine without aura |
| 33125303 | 2021 | Cohort/Case series | J Pain Palliat Care Pharmacother | Retrospective review of erenumab + onabotulinumtoxinA combination in intractable chronic migraine |
| 40596876 | 2025 | Cohort (switch study) | J Headache Pain | Tolerability of switching from erenumab to fremanezumab after erenumab-related adverse events |
| 35230406 | 2022 | Review/News summary | JAMA | Summary reporting erenumab as safe and effective in patients with migraine with aura |
Safety Considerations
Please refer to the SmPC for safety information.
Note: A blocking data gap (DG001 – TFDA label warnings/contraindications) prevents completion of the S1 safety screening stage for this candidate.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Erenumab’s CGRP-receptor mechanism is well supported for migraine broadly, and multiple RCTs and post-hoc/cohort analyses address the aura subgroup (including vascular safety), giving L2 evidence. However, no trial or publication isolates “migraine with brainstem aura” specifically, and this is not a true novel-indication repurposing case but a subtype extension of an already-established use.
To proceed, the following is needed:
- TFDA label warnings/contraindications (DG001, blocking — required before S1 safety evaluation can proceed)
- Formal MOA documentation from DrugBank (DG002)
- Taiwan/EU regulatory and market authorization status (currently absent from this evidence pack)
- Subtype-specific clinical data (trial or registry) for migraine with brainstem aura, rather than pooled aura-status subgroup analyses
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.